EGFR and head and neck squamous cell carcinoma: Given that resistance to chemotherapy agents, such as EGFR inhibitors, is a significant limitation in HNSCC treatment [33], we determined if BSO+AUR would sensitize confluent HNSCC cells to the EGFR inhibitor Erlotinib.